On October 16th, the release ceremony of the list of Top Ten Chongqing Science and Technology Innovation Figures of the Year in 2023 was held in the West Science City of Chongqing . Professor Qian Cheng, Chairman and Chief Scientist of Chongqing Precision Biotech, was elected as one of the top ten science and technology innovation figures in Chongqing in 2023. 

It is reported that the 2023 Top Ten Chongqing Science and Technology Innovation Person of the Year selection campaign is guided by the Propaganda Department of Chongqing Municipal Committee, sponsored by Chongqing Daily Newspaper Group, and supported by Chongqing Association for Science and Technology and Chongqing High-tech Zone Management Committee of Western Science City.

Professor Qian Cheng, doctoral supervisor, is a famous international expert and scholar in biomedicine and immunotherapy. He is the Director of National International Joint Research Center for Precision Medical Biotherapy of Ministry of Science and Technology of China and Chief Scientist of the Key Research and Development Program of the Ministry of Science and Technology of China. Professor Qian Cheng has published more than 200 papers in the international authoritative SCI journals, with a total impact factor of 1500. He was cited by SCI journals for more than 20,000 and has been selected into the list of "Elsevier Highly Cited Chinese Researchers" for many times, and applied for more than 80 PCT and national invention patents. He was one of the first overseas scientists to put forward the theory of gene combination therapy, and achieved the first breakthrough in the technology of immune cell therapy for solid tumors in the world. He led his team to develop advanced cellular immunotherapy technologies and drugs for cancer treatment in China, and was rated as one of the institutions with the largest number of immunotherapy pipelines in the world by the internationally renowned journal Nature Reviews Drug Discovery. At present, more than 2000 cases of terminal cancer patients have been successfully treated and cured by his immune cell technology throughout the country.

As the chairman and chief scientist of Chongqing Precision Biotech Co., Ltd., Professor Qian Cheng adhered the mission of "innovation for health" and led the R&D team to focus on malignant tumor treatment with gene editing and biosynthesis technology. After seven years' development, the company has built an R&D elite team of more than 300 members, and a 18,000-square-meter R&D platform for gene and cell drugs with advanced facilities and powerful functions in China.The company has six original platform system technologies, which open up the whole industrial chain of independent research and development, independent production and independent testing. The company also applied for 125 key invention patents, and made special layout in developed countries such as Europe and America.The company has been granted the implied license of three Class I CAR-T cell biological new drugs and six indications. The registered clinic is progressing smoothly and excellent clinical data have been obtained, and the products for childhood leukemia are expected to become the first CAR-T new drug for this indication in China. At the same time, in the treatment of solid tumors such as kidney cancer, colorectal cancer and gastric cancer, the company has obtained a number of registered clinical approvals, leading the world in promoting drug registration.